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Abstract
Objective To determine women’s satisfaction with pain relief using
patient controlled analgesia with remifentanil compared with epidural
analgesia during labour.
Design Multicentre randomised controlled equivalence trial.
Setting 15 hospitals in the Netherlands.
ParticipantsWomen with an intermediate to high obstetric risk with an
intention to deliver vaginally. To exclude a clinically relevant difference
in satisfaction with pain relief of more than 10%, we needed to include
1136 women. Because of missing values for satisfaction this number
was increased to 1400 before any analysis. We used multiple imputation
to correct for missing data.
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Intervention Before the onset of active labour consenting women were
randomised to a pain relief strategy with patient controlled remifentanil
or epidural analgesia if they requested pain relief during labour.
Main outcome measures Primary outcome was satisfaction with pain
relief, measured hourly on a visual analogue scale and expressed as
area under the curve (AUC), thus providing a time weighted measure
of total satisfaction with pain relief. A higher AUC represents higher
satisfaction with pain relief. Secondary outcomes were pain intensity
scores, mode of delivery, and maternal and neonatal outcomes. Analysis
was done by intention to treat. The study was defined as an equivalence
study for the primary outcome.
Results 1414 women were randomised, of whom 709 were allocated
to patient controlled remifentanil and 705 to epidural analgesia. Baseline
characteristics were comparable. Pain relief was ultimately used in 65%
(447/687) in the remifentanil group and 52% (347/671) in the epidural
analgesia group (relative risk 1.32, 95% confidence interval 1.18 to 1.48).
Cross over occurred in 7% (45/687) and 8% (51/671) of women,
respectively. Of women primarily treated with remifentanil, 13% (53/402)
converted to epidural analgesia, while in women primarily treated with
epidural analgesia 1% (3/296) converted to remifentanil. The area under
the curve for total satisfaction with pain relief was 30.9 in the remifentanil
group versus 33.7 in the epidural analgesia group (mean difference −2.8,
95% confidence interval −6.9 to 1.3). For who actually received pain
relief the area under the curve for satisfaction with pain relief after the
start of pain relief was 25.6 in the remifentanil group versus 36.1 in the
epidural analgesia group (mean difference −10.4, −13.9 to −7.0). The
rate of caesarean section was 15% in both groups. Oxygen saturation
was significantly lower (SpO2 <92%) in women who used remifentanil
(relative risk 1.5, 1.4 to 1.7). Maternal and neonatal outcomes were
comparable between both groups.
Conclusion In women in labour, patient controlled analgesia with
remifentanil is not equivalent to epidural analgesia with respect to scores
on satisfaction with pain relief. Satisfaction with pain relief was
significantly higher in women who were allocated to and received epidural
analgesia.
Trial registration Netherlands Trial Register NTR2551.
Introduction
Epidural analgesia is considered to be the most effective method
of pain relief during labour and is often the preferred choice of
analgesia.1 Intramuscular or intravenous opioids can provide an
alternative in situations where regional analgesia is unavailable
or contraindicated or if less invasive methods are preferred by
the woman or obstetrician.2 Remifentanil is a potent µ opioid
receptor agonist. Its short context sensitive half life (3-4minutes)
and short elimination half time (10-20 minutes) make it suitable
for administration under the control of the patient for women
in labour whowant pain relief.3 Placental transfer of remifentanil
occurs, but the opioid is rapidly metabolised and redistributed
by the fetus.4
Although epidural analgesia during labour is the preferred
method because it provides superior analgesia to systemic
opioids, various studies show comparable maternal satisfaction
with patient controlled remifentanil.5 6 Two previous studies
that assessed satisfaction with pain relief with patient controlled
remifentanil compared with epidural analgesia reported no
differences. Both studies, however, had limitations. Volmanen
and colleagues limited the observation period to only one hour
after the start of pain relief,5 while Douma and colleagues
recorded pain relief scores as a secondary outcome in a study
powered to investigate difference in pain scores.6 In both studies,
epidural analgesia was superior to patient controlled remifentanil
in terms of pain intensity.
The most recent Cochrane review on this topic recommended
a randomised controlled trial to examine patient controlled
analgesia with an opioid compared with other methods of
analgesia and to report on maternal satisfaction, cointerventions,
and maternal and neonatal outcomes.7We conducted this study
to test the hypothesis that patient controlled remifentanil is




We performed a multicentre randomised clinical trial within the
Dutch consortium for women’s health and reproductivity (NTR
2551). The study was performed in three academic hospitals,
11 teaching hospitals, and one general hospital. In the
Netherlands healthy low risk pregnant women start antenatal
care in primarymidwifery led care.Whenmedical complications
occur, either maternal or fetal, women are referred to secondary
or tertiary care. For this study we recruited only women in
secondary and tertiary care (intermediate/high risk). Women
are considered low risk if their medical and/or obstetric history
is uneventful. Women are considered intermediate or high risk
if they have illnesses in their medical history that can affect
pregnancy or that are affected by pregnancy or if they have
complications in this or previous pregnancies or deliveries.
Women were eligible to participate if they were healthy or had
a mild systemic disease (American Society of Anesthesiologists
physical classification 1 or 2),8were aged 18 or older, and were
scheduled to deliver vaginally after 32 weeks. Exclusion criteria
were contraindications for epidural analgesia or hypersensitivity
to one of the drugs used.
After informed consent, but before the onset of active labour,
women were randomly allocated to patient controlled
remifentanil or epidural analgesia. All women were randomised
before the start of actual labour. As analgesia during labour was




The patient controlled device was programmed to deliver 30 µg
remifentanil (solution 20 µg/mL) on request with a lockout time
of three minutes. This dose regimen was based on previous
studies.6 9 The dose could be increased to 40 µg in case of
insufficient pain relief or decreased to 20 µg in case of excessive
side effects. No background infusion was allowed.Women who
were treated patient controlled remifentanil were instructed on
how to use the device and to maximise analgesia by pressing
the device’s button in anticipation of the next contraction.
Remifentanil has a rapid onset of action and short context
sensitive half life, thus administration of a bolus dose in
anticipation of the next contraction ensures maximum effect.3
If pain relief was inadequate, women could request epidural
analgesia. They were advised to discontinue using the device
during the second stage of labour to minimise the risk of
neonatal side effects.
Epidural analgesia group
Women randomised to epidural analgesia received this when
they requested pain relief, according to local protocol. If pain
relief after epidural analgesia was judged inadequate by the
woman, she could receive patient controlled remifentanil instead
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of epidural analgesia. No advice was given regarding continuing
epidural analgesia during the second stage of labour. Dutch
guidelines advise the continuation of epidural analgesia during
second stage provided there is no effect on motor function.1
Data collection
During labour, women were asked two separate questions. They
were asked to rate their satisfaction with pain on a specially
designed ruler with a visual analogue scale ranging from 0
(highly dissatisfied) to 100 mm (highly satisfied). They started
from the beginning of actual labour and were asked to report
hourly. In addition, they were asked to rate the pain intensity
score during contractions every hour on a scale ranging from 0
(no pain) to 100 mm (worst pain imaginable).
For satisfaction with pain relief, womenwere asked to rate their
satisfaction with pain (relief) (“how would you rate your
satisfaction with pain relief?”) on a visual analogue scale. This
was described briefly in the patient information given to the
women before randomisation and in detail at admission for
delivery. For the pain intensity score, women asked to rate their
pain score (“how would you rate your pain during a
contraction?”) on a different visual analogue scale.
Written examples of these questions and how to use the VAS
ruler were available at the labour ward (see appendix 1). After
birth, women were asked to rate their overall satisfaction with
the pain during labour on an 11 point numerical rating scale as
a measure of the overall pain experience. They were not asked
to rate the overall experience of labour.
Maternal oxygen saturation was monitored continuously in
women receiving pain relief. The followingmeasurements were
obtained and recorded once before the start of analgesia and at
15 minute intervals during the first hour of treatment followed
by hourly recordings until delivery: maternal temperature, blood
pressure, heart rate and respiratory rate, and oxygen saturation
determined by pulse oximetry.
In women who received analgesia, the nurse, midwife, or
obstetrician recorded the incidence of nausea, vomiting, itching,
hypotension (systolic blood pressure <90 mmHg), desaturation
(SpO2 <92%), and respiratory depression (frequency <8/min).
Additional measures were advised in case of hypotension,
maternal desaturation, or respiratory depression.
Fetal heart rate and uterine activity were measured with external
fetal cardiotocography or fetal scalp electrode and intrauterine
pressure device.
Outcomes
The primary outcome measure was satisfaction with pain relief
measured on a visual analogue scale ranging from 0-100 mm.
Satisfaction was expressed as the area under the pain satisfaction
curve, which is a summary measure that integrates serial
assessments of a woman’s satisfaction with pain relief over the
duration of the study. The area under the curve (AUC) is a
measure that is often used in clinical pharmacology, but it can
also be used for clinical endpoints—for example, the use in pain
assessment.10-13 A higher AUC represents a higher satisfaction
with pain relief. The AUC was calculated for the duration of
labour and for the time that pain relief was administered. The
AUC could be calculated if a woman had rated satisfaction with
pain relief on at least two different time points.
Our published protocol stated that both effectiveness and cost
effectiveness were primary outcomemeasures. Satisfaction with
pain relief was the primary outcome measure for effectiveness
from the start of the study. We planned to perform a cost
effectiveness analysis as well, taking into account the primary
outcome for effectiveness. Because this was not made clear
enough in the original protocol and registry it was changed in
the last amended protocol. This last amended protocol was
submitted before the last randomised woman delivered and as
a result we did not have access to the data.14
Secondary outcome measures were the AUC for pain intensity
scores, score for overall satisfaction with pain relief during
labour, the highest pain intensity score during labour, pain
intensity and satisfaction with pain relief at the moment of
request for pain relief, highest score for satisfaction with pain
relief after pain relief was used, and the mean scores of pain
and satisfaction with pain relief.
We also recorded characteristics of labour (time from request
to start of analgesia, duration of analgesia, duration of second
stage, use of oxytocin, mode of delivery, reasons for
instrumental delivery), maternal outcomes (postpartum
haemorrhage (estimated blood loss >1000 mL), suspicion of
intrapartum infection (temperature >38.0oC and the use of
antibiotics), spinal headache, major maternal complications,
maternal parameters (temperature, blood pressure, oxygen
saturation, and respiratory rate)), and maternal admission. For
the neonate we assessed Apgar score at 5 minutes, arterial cord
blood pH, neonatal admission, and reasons for neonatal
admission.
Sample size calculation
We calculated our sample size based on the primary outcome
measure of satisfaction with pain relief, assuming that there
would be no difference in satisfaction (two sided test, α 0.05,
power 0.9). In this equivalence design, we would need 102
women to be treated in each group to exclude a potential
clinically relevant difference of 10% (on an 11 point scale,
estimated SD 2.2). Allowing for 30% and 10% cross over in
the remifentanil group and epidural analgesia group,
respectively, we needed 568 women in total. We estimated that
out of pregnant women who would be willing to participate in
the study, about half would actually request analgesia. We
therefore needed to randomise 1136 women. In anticipation of
missing data on the primary endpoint during the study period,
we extended the number of women to 1400 before any
comparative analysis.
This sample size was calculated based on a visual analogue
scale for satisfaction with pain relief at one time point. In
February 2013 we amended the protocol because we decided
to change the primary outcome from a score at one time point
to the area under the satisfaction curve, which integrates all
visual analogue scores measured over time. In our opinion the
AUC best represents the overall satisfaction with pain relief and
it can deal with missing values, but at the start of the trial we
were not well enough aware of this.
For this measure we also judged that 10% equals a clinically
relevant difference. Our sample size calculation was done on a
different outcome parameter. In the sample size calculations,
we used 10% reduction on the visual analogue scale for
satisfaction with pain relief as equivalence margin, which is one
point reduction in satisfaction with pain relief. As we changed
the primary outcome measure to a time weighted measure by
using the AUC, we could no longer use this equivalence margin.
We therefore used an equivalence margin of 10% of the mean
AUC.
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Interim analysis and stopping rules
We used specially designed forms to report serious adverse
events and suspected unexpected serious adverse reactions to
the ethics committee of the Leiden University Medical Centre.
A data safety monitoring board was established before the start
of the trial. No interim analysis was performed because of the
equivalence design of the trial. Serious adverse events and
reactions were reported to the board and medical ethics
committee to evaluate the safety of women. Predefined serious
adverse events were requirement for mechanical ventilation or
cardiopulmonary resuscitation, meningitis, and epidural
haematoma. Apart from that we asked to be informed about
respiratory depression <8 breaths/minute and oxygen saturation
<92% that did not respond to a decrease in bolus dose. These
events had to be reported to the principal investigator and to the
data safety monitoring board. If deemed necessary the data
safety monitoring board would be able to (temporarily) stop the
study.
Randomisation and blinding
Randomisation was performed through a web based
randomisation program.We randomised in fixed blocks of three,
stratified for centre and parity. The allocation code appeared
after a patient’s initials were entered into the randomisation
program.
All womenwere randomised before the start of labour. If women
requested pain relief during labour, the allocated intervention
was provided. Before labour, women did not have the option
of choosing analgesia other than according to randomisation.
Blinding was not possible because of the nature of the two
interventions. Research nurses/midwives as well as attending
medical staff performed randomisation.
Data analysis
The trial was designed as an equivalence trial for the primary
outcome measure AUC of satisfaction with pain relief and the
secondary outcome measure AUC of pain intensity. The other
secondary outcomes were analysed for superiority. Our null
hypothesis was that the difference in the score for satisfaction
with pain relief, scored on a visual analogue scale (0-100 mm),
between the two study groups would be greater than 10%.
Preliminary unpublished data in perioperative patients using
patient controlled opioid treatment had shown that changes (that
is, increases) in pain intensity scores of 10% or larger will
prompt action in a patient—that is, he or she will require
additional pain relief by pressing the device’s button.
Extrapolation of these data to the current study suggests that at
differences in visual analogue scores of 10% or more, clinical
differences in satisfaction with pain relief can be assumed. We
calculated the estimated standard deviation using data from
Volmanen and colleagues5 and converted those from a five point
to an 11 point scale.
Data were analysed on an intention to treat basis. We tested for
equivalence by determining whether the upper and lower limits
of the two sided 95% confidence interval on the primary
endpoint AUC of satisfaction with pain relief and the secondary
endpoint AUC of pain intensity did not exceed the equivalence
margin of 10%. Normally distributed data were presented as
means with SDs; skewed distributions were presented as
medians with interquartile range. For categorical data, the
treatment effect was presented as relative risk with 95%
confidence intervals. For secondary outcome measures we
calculated P values with the χ2 test, unless the expected cell
count was less than 5, in which case we used the Fisher’s exact
test. For continuous data with a non-normal distribution, we
used the Mann-Whitney U test.
Calculation of the percentages was based on the number of valid
observations. Statistical analysis was performed with SPSS
version 20 (SPSS, Chicago, IL). P<0.05 was considered
significant.
We performed two analyses. Firstly, we analysed the whole
group of randomised women on an intention to treat basis. This
analysis included women who did and did not receive any pain
relief (687 in remifentanil group, 671 in epidural group). In a
second analysis, we included only those women who actually
received pain relief (447 in remifentanil group, 347 in epidural
group). To correct for possible confounding in the second
analysis because a larger number of women who received pain
relief were in the group allocated to remifentanil, we also
compared the two randomisation groups in the subgroup of
women who actually received pain relief using multiple linear
regression, with adjustment for randomisation outcome, age,
race, education, parity, onset of labour, dilation at request of
pain relief, and premature labour.
Subgroup analyses
We planned subgroup analyses for satisfaction with pain relief
for nulliparous women versus multiparous women, previous
caesarean section, spontaneous versus induced labour,
educational level, aged under 36 versus 36 or older, gestational
age at delivery (<34 weeks, 34-37 weeks, >37 weeks), and
singleton versus multiple pregnancy.
Missing data
We used multiple imputation with SPSS to correct for missing
primary outcome data.15-17We imputed missing AUC values for
satisfaction with pain relief and pain intensity (transformed so
that the distribution was approximately normal) using 20
imputed datasets. Other missing values were not imputed.
Results
Between 30 May 2011 and 24 October 2012, we randomised
1414 women to receive patient controlled remifentanil (n=709)
or epidural analgesia (n=705) should they request analgesia
during labour. After randomisation, we excluded 51 women (22
in remifentanil group, 29 in epidural group) because of elective
caesarean section.
In the epidural group, three womenwere lost to follow-up, while
two withdrew informed consent after randomisation. We
analysed the data from 1358 women, 687 in the remifentanil
group and 671 in the epidural group (figure⇓). Baseline
characteristics were comparable between groups (table 1⇓).
Of the 709women randomised to patient controlled remifentanil,
447 (65%) actually received analgesia during labour, compared
with 52% (347) in the epidural analgesia group (relative risk
1.32, 95% confidence interval 1.18 to 1.48).
Of the 447 women in the remifentanil group who received pain
relief, 402 women received immediate remifentanil. Forty five
women received analgesia other than the allocated type: 41
received epidural analgesia, and four received other opioids. Of
the 402 women who started remifentanil, 53 women converted
to epidural analgesia because of insufficient analgesia (figure⇓).
Of women who were treated with remifentanil, 92% (411/447)
started with a dose of 30 µg; the other women were given an
initial dose of 20-40 µgr. In 13% (59/447) the dose was increased
once, and in 3% (14/447) it was decreased once. In 3% (12/447)
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and 0.7% (3/447) the bolus dose was increased twice or three
times, respectively.
Of the 347 women who requested pain relief and been allocated
to epidural analgesia, 296 received immediate epidural analgesia.
Fifty one women were received analgesia other than allocated
type: 33 were treated with remifentanil (of whom two women
converted back to epidural analgesia after remifentanil), and 18
received other opioids. Three women initially treated with
epidural analgesia converted to remifentanil because of
insufficient analgesia (figure⇓).
The epidural regimens used were ropivacaine/sufentanil (37%),
bupivacaine/sufentanil (46%), levobupivacaine/sufentanil (6%),
and bupivacaine/fentanyl (11%).
Reasons for non-compliance (treatment other than the
randomised outcome) included doctors’ or patients’
preference/request, expectation of quick or slow delivery,
logistical problems (for instance, non-availability of the
anaesthetist (within one hour)), and new contraindication for
randomised treatment (table 2⇓).
Missing data
We could calculate the primary outcome measure, AUC for
satisfaction with pain relief during active labour, for 57% of
women in the remifentanil group and 43% in the epidural group.
In the subgroup of women who received analgesia, the AUC
for satisfaction with pain relief during administration of pain
relief could be calculated for 71% and 57%, respectively.
The AUC for pain intensity score during active labour could be
calculated for 64% of participants in the remifentanil group and
53% in the epidural group. In the subgroup of women who
received analgesia the AUC for pain intensity score could be
calculated for 77% of women in the remifentanil group and 63%
in the epidural group. Characteristics of complete and
incomplete cases are in appendix 2.
Primary outcome
The AUC for satisfaction with pain relief during labour for all
randomised women was lower in the remifentanil group
(difference −2.8, 95% confidence interval −6.9 to 1.3). As this
does not exclude a potential clinically relevant difference, we
cannot conclude that the treatments are equivalent. Furthermore,
in the subgroup of women who actually received analgesia, the
AUC for satisfaction with pain relief after start of pain relief
was significantly lower in women who asked for pain relief and
were randomised to remifentanil (difference −10.4, −13.9 to
−7.0) (table 3⇓).
The AUC for pain intensity during labour for all randomised
women was higher in the remifentanil group (difference 3.8,
95% confidence interval 0.92 to 6.6). For the group of women
who actually received analgesia, the AUC for pain intensity
after the start of pain relief was significantly higher in women
who requested pain relief and were randomised to remifentanil
(difference 6.4, 3.5 to 9.4) (table 3⇓).
Table 3⇓ also shows the values without imputation for the AUC,
providing a larger effect size than the imputed values. Results
of the comparisons in the group of womenwho actually received
analgesia, with adjustment for possible confounders, were
similar: the difference in AUC for satisfaction with pain relief
after the start pain relief was −8.7 (95% confidence interval
−12.0 to −5.5) and the difference in AUC for pain score after
the start pain relief was 7.6 (4.8 to 10.4).
Secondary outcomes
Overall scores and means
The overall satisfaction score with pain during labour was not
significantly different between the study groups in the intention
to treat analysis, when we accounted for scores of women with
and without pain relief (6.9 remifentanil v 7.2 epidural,
difference −0.29, 95% confidence interval −0.60 to 0.01). In
women who received pain relief the overall satisfaction score
was significantly lower for women randomised to remifentanil:
6.8 for women randomised to remifentanil v 7.3 for women
randomised to epidural analgesia (difference −0.52, 95%
confidence interval −0.91 to −0.13).
Mean scores for satisfaction with pain relief were significantly
lower in the remifentanil group, both for the total period of
active labour and after the start of pain relief. Mean pain scores
for both periods were significantly higher in the remifentanil
group. Pain scores and satisfaction with pain relief at the time
when pain relief was requested were not significantly different
between the groups. Highest satisfaction with pain relief and
lowest pain intensity score after pain relief were significantly
different in favour of epidural analgesia (table 4⇓). These scores
were not imputed.
Characteristics of labour and maternal and
neonatal outcomes
The intervals from request for pain relief to the start of pain
relief and from start of pain relief to delivery were shorter in
the remifentanil group (table 5⇓). There were no other significant
differences in characteristics of labour andmaternal and neonatal
outcomes between the two study groups (table 5⇓).
In women who actually received analgesia, the only significant
difference in characteristics of labour and maternal and neonatal
outcomes was a shorter duration of second stage of labour in
women randomised to remifentanil (median duration 25,
interquartile range 11-51, minutes) compared with epidural
analgesia (34, 15-60; P=0.01).
Some side effects were reported more often in women who
received analgesia. Temperature was significantly higher and
hypotensionmore common in the womenwho received epidural
analgesia. Oxygen saturation was significantly lower with
remifentanil. There were four reported cases of respiratory
depressions of <8 breaths a minute in the remifentanil group
and none in the epidural group. Nausea was more common in
the group randomised to remifentanil, but vomiting and itching
were not (table 6⇓).
One serious adverse event was recorded: one woman who
received epidural analgesia presented with eclampsia on the
fourth day after delivery. There were no maternal deaths.
Postpartum admission, duration of admission, and reasons for
admission for mothers and neonates were comparable in both
groups (table 5⇓).
There were three intrauterine fetal deaths after randomisation,
all before the start of labour. These were two singletons at a
gestational age 41-42 weeks and the second twin of
monochorionic twins at 35+6 with suspicion of acute twin to
twin transfusion syndrome. Three neonates died postpartum,
two singletons and one twin, all from congenital defects that
were diagnosed during pregnancy (Zellweger syndrome, two
major cardiac defects).
Subgroup analyses for AUC for pain and satisfaction with pain
relief were performed as planned for all predescribed groups
except for gestational age at birth 32-34 weeks because only
one woman in the remifentanil group received pain relief.
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Results of subgroup analysis were similar to those of the whole
group, with no significant interactions found (see figs A-D in
appendix 3).
Discussion
Statement of principal findings
The results of this large multicentre trial show that patient
controlled analgesia with remifentanil is not equivalent to
epidural analgesia with respect to satisfaction with pain relief,
with poorer scores obtained in women treated with remifentanil.
This study also confirms the results of previous trials that
epidural analgesia provides superior pain relief when measured
in terms of pain intensity scores.5 6 18-20 These results were
consistent throughout all subgroups. In contrast with previous
studies that did not have sufficient power to detect a difference,
this is the first well powered study to showing that patient
controlled remifentanil is not equivalent to epidural analgesia
with respect to satisfaction with pain relief.
Significantly more women randomised to remifentanil actually
requested and received analgesia.We relate this to the perception
of women that remifentanil is less invasive and more easily
available. Furthermore, the time between the request for and
start of analgesia was shorter in the remifentanil group, probably
because an anaesthetist is not required.
Duration of analgesia (that is, the time from start of analgesia
to birth) was significantly longer in the epidural analgesia group.
One explanation might be the epidural analgesia slows labour
but there are other possible explanations. For example, in the
Netherlands it is still practice to wait for the urge to push (and
even to stop the epidural to increase sensation). This might cause
a delay in starting the second stage of labour.
An important finding from the secondary outcome measures is
the high incidence of desaturations, with oxygen saturations
below 92% in 18% and below 95% in 38% of women treated
with remifentanil, compared with 5% and 12% inwomen treated
with epidural analgesia (table 6⇓).
There were four reported respiratory depressions with <8 breaths
a minute in the remifentanil group, all during administration of
remifentanil. Although the difference in occurrence is not
significant, probably because of the low prevalence of
respiratory depression, and although there were about 25%
missing values, this is a potentially life threatening side effect
of remifentanil. Caregivers should be aware that serious
respiratory complications can occur during administration of
remifentanil (table 6⇓).19-22
Strengths and weaknesses
In the Netherlands there is a distinction between primary and
secondary/tertiary care in obstetrics. Women at low risk are
under antenatal care of community midwives; intermediate or
high risk women are under antenatal care of gynaecologists.
We included only women in secondary/tertiary care as we
assumed that opinions on labour and pain (satisfaction) are
different not only in the women but also in the obstetric team.
As we were interested in this possible difference, we started a
second study in low risk women in primary care. This study has
been completed and is under analysis.
We decided to use the area under the curve (AUC) as our
primary outcome as it included all available data from
responders and can be interpreted as an integral measure of total
satisfaction with pain relief rather than using satisfaction only
at a specific time point. The AUC gives a timeweightedmeasure
of total satisfaction with pain relief.
We measured satisfaction scores at one hour intervals during
active labour and used the AUC as a time weighted measure of
this index. Use of AUC requires multiple scores during labour.
This could have resulted in an increase in missing data as in
some women, especially those women who did not receive pain
relief, often just one measurement was available. Still we chose
this approach as pain AUC gives a time weighted and
consequently a more reliable measure of pain response than
single measurements.
Though we believe that a time weighted measure is the best
way to measure total satisfaction with pain relief, pain relief
was administered over a longer period of time in the epidural
analgesia group. This influences the AUC but it also influences
total pain experience (with a higher total satisfaction over a
longer period of time). To test if the difference in AUC between
the two study groups during administration of pain relief was
influenced by this difference we also analysed the AUC per
hour and mean satisfaction with pain relief on specific time
points. As these were also significantly lower in the remifentanil
group, we believe the total AUC is only minimally influenced
by this extra time.
The main weakness of our study was the percentage of missing
values for satisfaction with pain relief and pain intensity. The
AUC for satisfaction with pain relief during active labour could
be calculated for 57% of women in the remifentanil group and
43% in the epidural group. In the subgroup of women who
actually received analgesia, the AUC for satisfaction with pain
relief during administration of pain relief could be calculated
for 71% and 57%, respectively.
As mentioned above, multiple measurements are necessary to
calculate the AUC. One explanation for the missing data is
reluctance of caregivers to focus on pain in women who are not
asking for pain relief. Another reason might be that epidural
analgesia is routine so extra measurements are more easily
forgotten. We opted to use imputation to correct for these
missing values, assuming that scores for satisfaction with pain
relief were missing at random. Hence, we judged that imputation
would give a more accurate representation of total satisfaction
with pain relief than the exclusion of women with just one or
no data points.15 The groups with complete and incomplete data
were similar on all baseline characteristics and most labour
characteristics. They were, however, significantly different on
onset of labour, request for pain relief, and mode of delivery,
with fewer scores obtained from women in spontaneous labour
who did not receive pain relief and delivered spontaneously
(appendix 2). This could be explained by shorter duration of
labour and shorter time in hospital for those women.
Furthermore, analyses without imputed values showed similar
differences in AUC for pain intensity and satisfaction with pain
relief.
As randomisation was performed antenatally, women knew
their allocated intervention when in need for pain relief during
labour. We chose this design to mimic daily practice, where a
woman knows which methods of pain relief are available and
which one she will most likely receive. Because masking of
treatment was considered unethical, crossovers might have
occurred because of preferences of doctors or women for one
of the two treatments in light of labour characteristics. This
could have influenced study outcome to some extent. But as the
percentage of non-compliance in both groups was around 10%,
lower than the number we anticipated in the power analysis, we
think this influence wasminimal. Furthermore, in an equivalence
design non-compliance will provide an underestimation of the
effect, making it more plausible that there truly is no equivalence
between both interventions.
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Explanation and implication for clinicians and
policymakers
Although patient controlled remifentanil does improve pain and
scores for satisfaction with pain relief, our study shows that this
improvement is not optimal when compared with improvement
of scores with epidural analgesia. As scores for satisfaction with
pain relief were lower and pain intensity scores higher in women
randomised to remifentanil, we cannot suggest it as an equivalent
alternative to epidural analgesia. The higher percentage of
women who actually received pain relief in the remifentanil
group could suggest that there is a need for other types of
analgesia options besides epidural analgesia and that women
and/or caregivers perceive remifentanil as less invasive and
hence easier to administer and possibly also less harmful.
Another explanation might be that remifentanil is more readily
available than epidural analgesia because the presence of an
anaesthetist is not required. Either patient controlled remifentanil
is a much needed addition to the possibilities of analgesia or
we should still make epidural analgesia more accessible for all
women who request pain relief during labour.
Delivery outcome and labour characteristics were not different
between groups nor were maternal and neonatal morbidity. But
we did find a significant difference in respiratory side effects
in women treated with remifentanil. Remifentanil is a potent
opioid and should be used with appropriate monitoring and the
ability to intervene if respiratory complications arise.20 21Women
should be counselled on the effects and side effects of both
remifentanil and epidural analgesia.
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What is already known on this topic
Epidural analgesia is considered to be the most effective method of pain relief during labour
Satisfaction with pain relief might be comparable between patient controlled remifentanil and epidural analgesia
What this study adds
Patient controlled remifentanil is not equivalent to epidural analgesia and performs worse in terms of women’s satisfaction with pain
relief
Significantly more women randomised to remifentanil actually requested and received analgesia
As more women allocated to remifentanil had respiratory complications, caregivers should be aware that such complications can occur
with this drug
Tables
Table 1| Baseline characteristics of pregnant women allocated to patient controlled remifentanil or epidural analgesia in labour. Figures
are numbers (percentage) unless otherwise indicated
Epidural analgesia (n=671)Remifentanil (n=687)
37.1 (35.3-39.0)37.8 (35.5-39.2)Median (IQR) gestational age at randomisation (weeks)
31.7 (4.8)31.5 (5.1)Mean (SD) maternal age (years)
561 (90)†579 (88)*White ethnic origin
296 (55)§281 (52)‡Education ≥higher







30 (5)24 (4)Multiple pregnancy
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Table 2| Pregnant women allocated to patient controlled remifentanil or epidural analgesia in labour who received the other measured
intervention
Randomised to remifentanil, received epidural
analgesia (n=41)








*Family history of Rendu-Osler-Weber syndrome, aortic valve stenosis, HELLP syndrome with thrombocyte count of 36.
†Opioids administered <6 hours, initial maternal SpO2 <95%, initial maternal temperature >38° C.
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Table 3| Area under curve for satisfaction with pain relief and pain scores during active labour and after start pain relief in pregnant women
allocated to patient controlled remifentanil or epidural analgesia in labour
Mean area under curve
Measure (No of women per group) Difference (95% CI)Epidural analgesiaRemifentanil
With missing AUC values imputed
−2.8 (−6.9 to 1.3)33.730.9Satisfaction with pain relief during active labour (687/671)
−10.4 (−13.9 to −7.0)36.125.6Satisfaction with pain relief after pain relief (447/347*)
3.8 (0.92 to 6.6)27.230.9Pain during active labour (687/671)
6.4 (3.5 to 9.4)20.326.7Pain score after pain relief (447/347*)
Missing AUC values not imputed
−10.3 (−14.6 to −6.1)37.627.2Satisfaction with pain relief during active labour (394/290)
−15.7 (−20.2 to −11.2)41.325.5Satisfaction with pain relief after pain relief (316/198†*)
4.9 (1.7 to 8.1)24.929.7Pain during active labour (438/354)
7.0 (3.3 to 10.7)21.027.8Pain score after pain relief (345/220†)
*No who actually received pain relief.
†No who reported sufficient scores to calculate AUC and received pain relief.
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Table 4| Secondary outcomes for mean (SD) pain scores and scores for satisfaction with pain relief in pregnant women allocated to patient
controlled remifentanil or epidural analgesia in labour. Missing values were not imputed
P valueDifference (95% CI)Epidural analgesiaRemifentanil
<0.001−0.77 (−1.1 to −0.43)5.9 (2.5)5.1 (2.3)Satisfaction with pain relief during active labour
<0.001−1.7 (−2.1 to −1.3)7.0 (2.5)5.3 (2.3)Satisfaction with pain relief after pain relief
0.63−0.12 (−0.58 to 0.35)4.34.2Satisfaction with pain relief at request pain relief
<0.001−1.5 (−2.0 to −1.1)8.4 (2.3)6.9 (2.7)Highest satisfaction with pain relief after pain relief
<0.0010.74 (0.46 to 1.0)5.2 (2.3)6.0 (1.9)Pain during active labour
<0.0011.9 (1.5 to 2.3)4.2 (2.3)6.1 (1.9)Pain after pain relief
0.870.03 (−0.32 to 0.38)7.7 (2.5)7.7 (2.4)Pain at request pain relief
<0.0012.3 (1.9 to 2.7)1.7 (2.3)4.0 (2.6)Lowest pain score after pain relief
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Table 5| Characteristics of labour in pregnant women allocated to patient controlled remifentanil or epidural analgesia according to intention
to treat analysis. Figures are numbers (percentage) unless otherwise indicated
P valueRelative risk (95% CI)Epidural analgesia (n=671)Remifentanil (n=687)
0.37—39.7 (38.3-40.7)39.7 (38.3-40.7)Median (IQR) gestational age at delivery (weeks)
Onset of labour:
0.760.98 (0.88 to 1.09)281 (42)282 (41)Spontaneous
0.761.02 (0.91 to 1.32)390 (58)405 (59)Induced
<0.0011.32 (1.18 to 1.48)347 (52)447 (65)Requested pain relief
0.94—4 (3-5)4 (3-5)Median (IQR) dilation (cm) at request
Fetal condition at start pain relief (cardiotocography) (n=794):
0.710.96 (0.80 to 1.17)315 (91)400 (90)Optimal
—32 (9)44 (10)Not optimal
0.570.95 (0.80 to 1.13)80 (12)†76 (11)*Meconium stained amniotic fluid
0.610.97 (0.87 to 1.08)391 (58)394 (58)Augmentation with oxytocin
0.921.01 (0.83 to 1.24)48 (7)50 (7)>24 hours since rupture of membranes
<0.001—55 (32-80)28 (15-45)Median (IQR) time (min) from request to start analgesia
<0.001—309 (181-454)236 (128-376)Median (IQR) duration of analgesia (min)
0.09—24 (10-53)20 (10-46)Median (IQR) duration second stage (min)
Mode of delivery:
0.751.01 (0.90 to 1.15)501 (75)518 (75)Spontaneous
0.450.93 (0.77 to 1.13)70 (10)63 (9)Vaginal instrumental
0.871.01 (0.88 to 1.17)100 (15)106 (15)Caesarean section
0.130.86 (0.69 to 1.06)66 (10)§52 (8)‡Postpartum haemorrhage (≥1000 mL)
0.200.74 (0.44 to 1.25)15 (2)9 (1)Apgar score <7 at 5 min twin 1
0.340.86 (0.63 to 1.19)28 (6)**22 (5)¶Twin 1 pHa <7.10
0.210.24 (0.03 to 2.18)4 (0.6)‡‡1 (0.1)††Spinal headache
0.170.33 (0.07 to 1.61)6 (0.9)2 (0.3)Major maternal complication
0.700.98 (0.88 to 1.09)416 (62)419 (61)Maternal admission
0.24—1 (1-3)1 (1-3)Median (IQR) length of admission (days)
0.820.99 (0.89 to 1.10)385 (57)390 (57)Neonatal admission
0.13—1 (1-3)1 (1-3)Median (IQR) length of admission twin 1 (days)
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Table 6| Maternal side effects during administration of analgesia in pregnant women allocated to patient controlled remifentanil or epidural
analgesia in labour. Figures are numbers (percentage) unless otherwise indicated
No (%) with missing data
P valueRelative risk (95% CI)Epidural analgesia (n=347)Remifentanil (n=447) EpiduralRemifentanil
Temperature °C during labour:
35 (10.1)41 (9.2)<0.0010.66 (0.50 to 0.86)55 (18)35 (9)>38 °C
Maximum reported:
35 (10.1)41 (9.2)<0.001—37.3 (36.7-37.8)37.0 (36.6-37.4)Median (IQR)
————35.1-40.435.0-39.4Range
Saturation %:
45 (13.0)32 (7.2)<0.0011.63 (1.46 to 1.82)37 (12)154 (37)<95%
73 (21)58 (13)<0.0011.52 (1.35 to 1.71)14 (5)71 (18)<92%
Minimum reported:
73 (21)58 (13)<0.001—97 (96-98)95 (93-97)Median (IQR)
————76-10050-100Range
19 (5.5)26 (5.8)0.030.75 (0.57 to 1.00)38 (12)29 (7)Hypotension (<90 mm Hg systolic)
99 (28.5)83 (18.6)0.15—0 (0)4 (1)Respiratory depression
138 (39.8)150 (33.6)0.011.27 (1.09 to 1.49)25 (12)62 (21)Nausea
134 (38.6)145 (32.4)0.121.16 (0.97 to 1.38)28 (13)55 (18)Vomiting
144 (41.5)156 (34.9)0.10.77 (0.54 to 1.10)20 (10)17 (6)Itching
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Randomisation and flow of pregnant women allocated to patient controlled remifentanil or epidural analgesia in labour
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